Claims

1. An antibody binding the C-terminal fibrinogen-like domain of angiopoietin like 4 protein (cANGPTL4), said antibody comprising a heavy chain and a light chain, the heavy chain comprising a V_H CDR1, a V_H CDR2, and a V_H CDR3, and the light chain comprising a V_L CDR1, a V_L CDR2, and a V_L CDR3, wherein: said V_L CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO:3; said V_L CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO:4; said V_L CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO:5; said V_H CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO:6; said V_H CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO:7; and said V_H CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO:8.

2. The antibody of claim 1, wherein the heavy chain comprises a V_H domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:1 and the light chain comprises a V_L domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO:2.

3. The antibody of claim 1 or 2, wherein the antibody is an IgG1 kappa immunoglobulin.

4. The antibody of claim 3, wherein the antibody comprises a human IgG1 constant region within a heavy chain of the immunoglobulin and a human IgG1 constant region within a light chain of the immunoglobulin.

5. The antibody of claim 3, wherein the antibody comprises a fully human framework region within the variable domain of said heavy chain and within the variable domain of said light chain.

6. The antibody of claim 3, wherein the antibody comprises murine framework regions within the variable domain of the heavy chain and within the light chain.

7. The antibody of any one of claims 1-6 to for use in a method for treating a tumor.

8. An in vitro method of reducing cell proliferation, wherein the method comprises contacting proliferating cells with an antibody according to any one of claims 1 to 6.

9. A nucleic acid molecule encoding the antibody of any one of claims 1-6.

10. The nucleic acid molecule of claim 9, wherein the nucleic acid molecule comprises a nucleotide sequence encoding the variable domain of the light chain having the nucleotide sequence set forth in SEQ ID NO:9.

11. The nucleic acid molecule of claim 10, wherein the nucleic acid molecule comprises a nucleotide sequence encoding the variable domain of the heavy chain having the nucleotide sequence set forth in SEQ ID NO:10.

12. A composition for treating cancer comprising the antibody of any one of claims 1 to 6 and a carrier.

13. The composition of claim 12 further comprising one or more additional anti-cancer agents.